7AA (cyclic) Extensive Human
PT-141 (Bremelanotide)
FDA-approved melanocortin agonist that activates sexual desire via hypothalamic MC4R signalling — the only on-demand peptide for HSDD.
In Plain English: PT-141 works in the brain, not below the belt. By activating melanocortin-4 receptors in the hypothalamus, it triggers dopamine pathways that create genuine sexual desire. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, and studied off-label for sexual dysfunction in men.
Research Maturity
Extensive Human (116 results on PubMed for 'bremelanotide OR PT-141' (verified 2026-05-04)+ Studies)
Quick Facts
Focus
Female Sexual Interest/Arousal Disorder (FDA-approved)
Sexual Function
Route
SubQ
Origin
Synthetic carboxylated cyclic analogue of alpha-MSH, derived from Melanotan II after researchers noticed potent sexual arousal as a side effect. Developed by Palatin Technologies; FDA approved as Vyleesi June 2019.
Mechanism
Non-selective MC1R/MC3R/MC4R/MC5R agonist. Sexual desire via MC4R in medial preoptic area of hypothalamus. Binding triggers presynaptic dopamine and norepinephrine release in limbic circuits. Central CNS mechanism — does not act on peripheral vascular tissue like PDE5 inhibitors.
Outcome
Phase 3 RECONNECT (n=1,267): FSFI-D score +0.35 (p<0.001), FSDS-DAO -0.33 (p<0.001), ~58% responder rate. Male ED: 34% response vs 9% placebo in sildenafil-resistant patients. Onset 30-60 min, duration 6-12 hours.
Safety Flags & Warnings
Nausea (40% Incidence)
Transient BP Elevation
Focal Hyperpigmentation
Cardiovascular Contraindication
Off-Label for Men
Always consult a licensed physician. Research purposes only.
€3.0 / mg
